Pharmaceutical protein production by yeast: Towards production of human blood proteins by microbial fermentation

Since the approval of recombinant insulin from Escherichia coli for its clinical use in the early 1980s, the amount of recombinant pharmaceutical proteins obtained by microbial fermentations has significantly increased. The recent advances in genomics together with high throughput analysis technique...

Full description

Bibliographic Details
Main Authors: Martínez, J., Liu, Lifang, Petranovic, D., Nielsen, J.
Format: Journal Article
Published: 2012
Online Access:http://hdl.handle.net/20.500.11937/30466
_version_ 1848753096936652800
author Martínez, J.
Liu, Lifang
Petranovic, D.
Nielsen, J.
author_facet Martínez, J.
Liu, Lifang
Petranovic, D.
Nielsen, J.
author_sort Martínez, J.
building Curtin Institutional Repository
collection Online Access
description Since the approval of recombinant insulin from Escherichia coli for its clinical use in the early 1980s, the amount of recombinant pharmaceutical proteins obtained by microbial fermentations has significantly increased. The recent advances in genomics together with high throughput analysis techniques (the so-called - omics approaches) and integrative approaches (systems biology) allow the development of novel microbial cell factories as valuable platforms for large scale production of therapeutic proteins. This review summarizes the main achievements and the current situation in the field of recombinant therapeutics using yeast Saccharomyces cerevisiae as a model platform, and discusses the future potential of this platform for production of blood proteins and substitutes. © 2012 Elsevier Ltd.
first_indexed 2025-11-14T08:19:05Z
format Journal Article
id curtin-20.500.11937-30466
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T08:19:05Z
publishDate 2012
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-304662018-03-29T09:09:01Z Pharmaceutical protein production by yeast: Towards production of human blood proteins by microbial fermentation Martínez, J. Liu, Lifang Petranovic, D. Nielsen, J. Since the approval of recombinant insulin from Escherichia coli for its clinical use in the early 1980s, the amount of recombinant pharmaceutical proteins obtained by microbial fermentations has significantly increased. The recent advances in genomics together with high throughput analysis techniques (the so-called - omics approaches) and integrative approaches (systems biology) allow the development of novel microbial cell factories as valuable platforms for large scale production of therapeutic proteins. This review summarizes the main achievements and the current situation in the field of recombinant therapeutics using yeast Saccharomyces cerevisiae as a model platform, and discusses the future potential of this platform for production of blood proteins and substitutes. © 2012 Elsevier Ltd. 2012 Journal Article http://hdl.handle.net/20.500.11937/30466 10.1016/j.copbio.2012.03.011 restricted
spellingShingle Martínez, J.
Liu, Lifang
Petranovic, D.
Nielsen, J.
Pharmaceutical protein production by yeast: Towards production of human blood proteins by microbial fermentation
title Pharmaceutical protein production by yeast: Towards production of human blood proteins by microbial fermentation
title_full Pharmaceutical protein production by yeast: Towards production of human blood proteins by microbial fermentation
title_fullStr Pharmaceutical protein production by yeast: Towards production of human blood proteins by microbial fermentation
title_full_unstemmed Pharmaceutical protein production by yeast: Towards production of human blood proteins by microbial fermentation
title_short Pharmaceutical protein production by yeast: Towards production of human blood proteins by microbial fermentation
title_sort pharmaceutical protein production by yeast: towards production of human blood proteins by microbial fermentation
url http://hdl.handle.net/20.500.11937/30466